ISPOR 2020: do managed entry agreements for ATMPs exist in Germany? Curative and genetic therapies abstract highlights

Written by The Evidence Base
Decision science Health technology assessment ISPOR Medical devices, pharmaceuticals and vaccines Methodology News Rare diseases and orphan drugs

What research was due to have been presented at the 2020 ISPOR Annual Meeting (18–20 May)? We summarize our abstract highlights, available to view online, focusing on curative, regenerative and genetic therapies. The Evidence Base® is proud to be partnering with ISPOR to bring you coverage of the newly redesigned virtual 2020 meeting, including plenary summaries, exclusive interviews with speakers and more! Check out our dedicated channel to view the latest coverage>> Interested in partnering with The Evidence Base®? Contact us today>>> Here, we share our abstract highlights, due to have been presented at the annual meeting, focusing on curative, regenerative...

To view this content, please register now for access

It's completely free